Delayed engraftment, graft failure, and adverse transplant-related events have been observed in unrelated umbilical cord blood (UCB) recipients, particularly in those receiving a low leukocyte cell dose and in CML patients. We report the outcomes of two older adult patients with high risk CML who received a low leuko- 1,2 The limited availability of unrelated donor UCB units of adequate nucleated cell dose, however, restricts its application in older adult patients. Ex vivo expansion of UCB in small and clinical-scale regulated perfusion experiments (AastromReplicell System, Ann Arbor, MI, USA) has been proven capable of significantly increasing the number of total nucleated cells, CFU-GM, and longterm culture initiating cells.
Transplantation of umbilical cord blood (UCB) from related and unrelated donors has been performed in an attempt to increase the number of potential allogeneic stem cell donors. 1, 2 The limited availability of unrelated donor UCB units of adequate nucleated cell dose, however, restricts its application in older adult patients. Ex vivo expansion of UCB in small and clinical-scale regulated perfusion experiments (AastromReplicell System, Ann Arbor, MI, USA) has been proven capable of significantly increasing the number of total nucleated cells, CFU-GM, and longterm culture initiating cells. 3 Therefore, the effect of supplementing unrelated donor UCB with ex vivo expanded UCB cells from the same donor was evaluated in two older adult patients with high risk CML and no alternative donor. 
Case report

Patients
The first patient, a 48-year-old (107 kg) CMV seropositive male, presented in October 1996 with CML in chronic phase (46 XY t(9;22)(q34q11.2) [13]/48, XY, +8). Following an initial response to hydroxyurea and interferon alpha-2B, he developed myeloid blast crisis (May 1997). Idarubicin and cytarabine treatment resulted in a return to chronic phase. However, in October 1997, he experienced a recurrence of blast crisis. Preparative therapy for allogeneic transplant was immediately initiated.
The second patient, a 56-year-old (72 kg) CMV seronegative female, presented in September 1993 with CML (46 XX t(9;22)(q34q11.2)). She responded to treatment with interferon and hydroxyurea until May 1998 when she progressed to accelerated phase. Preparative therapy for allogeneic transplant was initiated on September 9, 1998.
Expansion of umbilical cord blood units
Cryopreserved UCB units for both patients were acquired from female donors (New York Blood Center, NY) after unsuccessful related and unrelated donor searches were conducted, and written consent approved by the institutional review board was obtained. The first patient's unit was CMV negative and an HLA match at A (1,2), B (8,−); and DRB1 (0301). The second patient's unit was CMV negative and an HLA match at A (1,2) and at DRB1 (701,1104), but a one antigen serologic mismatch at the B locus (patient 8,44; donor 8,51). The units were thawed, washed in dextran and albumin, and divided with approximately 89% (first patient) and 83% (second patient) of the unexpanded units infused on day 0 (Table 1) . 4 The remaining viable nucleated cells of each patient's unit were inoculated into the AastromReplicell System and perfused with media as described previously. 3 The expanded cells were harvested on day 12, washed, counted and infused within 4 h of harvesting (Table 1) . 
Transplantation
The first patient received a preparative regimen consisting of oral busulfan (4 mg/kg daily, days −7 to −4 not adjusted by blood level), anti-thymocyte globulin (ATG-Horse; Upjohn, Kalamazoo, MI, USA) (30 mg/kg daily, days −5 to −3) and cyclophosphamide (60 mg/kg daily, days −3 to −2). The second patient received 1200 cGy of total body irradiation with lung shielding (150 cGy twice daily, days −7 to −4), ATG (30 mg/kg daily, days −5 to −3) and cyclophosphamide (60 mg/kg daily, days −3 to −2). Prophylaxis for infection included oral ciprofloxacin and low-dose amphotericin-B. Intravenous antibiotics were substituted for body temperatures of у38.5°C. Cyclosporine, methylprednisolone (0.25 mg/kg) and intravenous immune globulin were used to prevent GVHD. Both patients received daily G-CSF (5 g/kg), starting on day 0 and continuing until achieving a neutrophil count of Ͼ1.5 × 10 3 cells/l for 3 consecutive days.
Results and discussion
In a recent report, 160 of 562 patients receiving UCB transplants failed to achieve myeloid engraftment. 5 The likelihood of successful myeloid engraftment was significantly reduced in patients who received a low leukocyte cell dose (0.7-2.4 × 10 7 /kg), and in HLA mismatched recipients. Of note, CML patients were reported to have an increase in the incidence of delayed engraftment, graft failure, and adverse non-relapse transplant-related events that included death, autologous reconstitution and receipt of a second transplant. Moreover, the Kaplan-Meier estimates of the cumulative incidence of these adverse transplant-related events exceeded 75% by 240 days after transplantation in patients older than 17 years, who received a nucleated cell dose of Ͻ2.5 × 10 7 /kg and those with a diagnosis of CML. In addition, an analysis of 133 cord blood transplants listed in the Eurocord Registry also revealed myeloid engraftment failures, occurring in 47% of patients over 15 years of age who had received less than 3.7 × 10 7 /kg nucleated cord blood cells. 6 Substantial delays in engraftment were also observed in this group of patients.
Therefore, expecting a delay or failure to engraft, two older adults with high risk CML and UCB units of low leukocyte cell dose, took part in an ongoing clinical trial of pediatric and adult patients receiving a combination of ex vivo expanded and unmanipulated UCB. Neutrophil count recovery in the first and second patient to 0.5 (31 and 25 days) and 1.0 × 10 3 /l (33 and 34 days after day 0) was observed as was transfusion-independent platelet recovery to 20 (52 and 60 days after day 0), 50 (92 and 97 days) and 100 × 10 3 cells/l (147 and 142 days). Neither patient experienced acute GVHD and there were no significant non-hematologic (grade IV) toxicities (including infection) observed post transplant, other than transient congestive heart failure experienced by the first patient. The second patient experienced a maximum body temperature of 38.3°C and, therefore, never required intravenous antibiotics. Complete cytogenetic remission and donor chimerism were confirmed on the initial marrow and blood assessments performed 74 and 43 days after transplant, in the first and second patient, respectively. Both patients, reassessed at 19 and 8 months post transplant, were found to remain in a clinical and cytogenetic remission with blood cells exclusively of donor origin. Neither patient had chronic GVHD, or late viral or fungal infections. Both currently have an Eastern Cooperative Oncology Group performance status of 0.
The addition of the expanded cells did not substantially increase the total number of leukocytes infused nor did it extend the UCB cell dose above the range associated with poor outcomes. Nevertheless, neutrophil and platelet engraftment occurred promptly when compared to the observed median days to 500 neutrophils/l (35 days) and 50 000 platelets/l (120 days) among unrelated umbilical cord blood recipients reported elsewhere who received a nucleated cell dose of 0.7-2.4 × 10 7 /kg. 5 Moreover, neither patient experienced an adverse transplant-related event. Facilitation of engraftment by the expanded UCB in this setting is supported by data we have generated during a recent trial designed to evaluate the effect of ex vivo expanded small volume (60-80 cc) bone marrow transplantation on blood count recovery kinetics in the setting of poor mobilization in patients with breast cancer. 9 In that study, transplantation of low doses of blood-derived CD34 + cells (0.5 × 10 6 /kg), when transplanted in combination with a marrow expanded ex vivo in the AastromReplicell System, produced hematopoietic recovery rates equivalent to those in a group of patients receiving a median of 10 × 10 6
CD34
+ cells/kg without marrow. Moreover, the prompt and complete recovery of marrow function observed in these UCB patients may partially explain the absence of GVHD, and other adverse events, via a mechanism of reduced secondary cytokine release compared to patients with prolonged aplasia. As shown previously, by virtue of a selective suppression of CD3 + cell growth, the ex vivo expanded bone marrow may also be less capable of mounting or exacerbating an effective T cell-mediated GVHD event after transplantation. 3 The outcomes in the two patients described here demonstrate that ex vivo expansion of unrelated UCB is a feasible and potentially appropriate therapy for older adult patients with high risk CML and low cell dose UCB units. Completion of ongoing studies is needed to determine if similar improvements in outcome will be observed in future patients with CML, and at even lower UCB doses. Moreover, through identification of the hematopoietic and/or accessory cells that facilitate engraftment and by optimization of the infusion sequence of expanded and unexpanded cells as reported elsewhere, 10 it may be possible to develop better expansion strategies that translate into a more consistent improvement in outcomes for unrelated UCB recipients.
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